Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

BACKGROUND: Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously treated advanced squamous (SQ) and non‐squamou...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Med
Main Authors: Horinouchi, Hidehito, Nishio, Makoto, Hida, Toyoaki, Nakagawa, Kazuhiko, Sakai, Hiroshi, Nogami, Naoyuki, Atagi, Shinji, Takahashi, Toshiaki, Saka, Hideo, Takenoyama, Mitsuhiro, Katakami, Nobuyuki, Tanaka, Hiroshi, Takeda, Koji, Satouchi, Miyako, Isobe, Hiroshi, Maemondo, Makoto, Goto, Koichi, Hirashima, Tomonori, Minato, Koichi, Sumiyoshi, Naoki, Tamura, Tomohide
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Clinical Cancer Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718542/
https://ncbi.nlm.nih.gov/pubmed/31353840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2411
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker